The role of angiogenesis blockers in the treatment of metastatic ovarian cancer

Abstract

High incidence of ovarian cancer, the identification of the majority of patients in late stages (65–70% – III–IV stage), short-term survival until relapse, repeated following surgeries and chemotherapy determine the necessity of search for effective treatment regimens. Nowadays platinum-based chemotherapy in addition with targeted therapy (bevacizumab) is standard chemotherapy for first and second line of advanced ovarian cancer. To improve the results of survival, further study of the use of bevacizumab in combination with chemotherapy in the subsequent lines of therapy for metastatic ovarian cancer is necessary.

Keywords

• metastatic ovarian cancer
• chemotherapy
• inhibition of angiogenesis